MiSight® Spectacle Lenses
Act early to help slow myopia progression
Demonstrated safe and effective for children as young as 6 in a multi clinical trial1*
59% reduction in myopia progression, on average, in children with full time wear over 2 years.1†
How MiSight® Spectacle Lenses Work
MiSight® Spectacle Lenses with Diffusion Optics Technology™ is a new and unique lens technology which reduces contrast to help slow axial elongation in myopia.2
MiSight® Spectacle Lenses were particularly effective in the youngest patients, aged 6-7 years old, who have the fastest progression, where no other spectacles have been evaluated for effectiveness.1
Children readily adapt to Diffusion Optics Technology™1
MiSight® Spectacle Lenses are designed to fit seamlessly into your practice
MiSight® Spectacle Lenses are prescribed like many other single-vision spectacle lenses.1¶
Eye Examination
Dispensing
Collection
*MiSight® Spectacle Lenses are indicated in Canada for the correction of refractive ametropia (myopia and/or astigmatism) and for the reduction in the rate of myopic progression in phakic children who are aged 6 to 13 years old with non-diseased eyes. Please refer to Instructions for Use (IFU) for information on product description, materials, parameters, indications, contraindications, warnings, and potential complications.
† Compared to control spectacle lenses over 24 months. Analysis based on parent responses to in-office question, “Does your child remove their spectacles for any near vision activities?” (n=51 test, n=62 control). For the full study cohort, reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average respectively.
‡ MiSight Spectacle Lenses are indicated to be worn constantly for all activities except for those outlined in WARNINGS (a minimum of 10 hours per day)
§ Proportion agreeing to “I love my glasses” at the 30-day, 6-month, 12-month, 18-month, and 24-month visits.
|| Proportion agreeing to “My glasses make me look cool” at the 30-day, 6-month, 12-month, 18-month, and 24-month visits.
¶ Pupil center height measurements required.
References:
1. SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n = 256, 14 North American sites).
2. Rappon J, et al. CYPRESS 12-month Results: Safety and Efficacy from a Pivotal Study of Novel Spectacle Lenses Designed to Reduce Myopia Progression. Optometry and Vision Science. 2020;97:E-abstract 200036.
3. Rappon J, et al. Novel DOT Lenses from SightGlass Vision Show Great Promise to Fight Myopia. Review of Myopia Management. Available at: http://reviewofmm.com/novel-dot-lenses-from-sightglass-vision-show-great-promise-to-fight-myopia/ [Accessed January 2024]
4. Rappon J, et al. Tolerability of novelmyopia control spectacle designs. Investigative Ophthalmology & Visual Science. 2019;60(9):5845-5845;